70872-24-1

Basic information

• Product Name: 2-Propen-1-one, 1-[2-hydroxy-4,6-dimethoxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-methoxy phenyl)-
• CAS NO: 70872-24-1
• Molecular Formula: C23H26O5
• Molecular Weight: 382.456
• Mol File: 70872-24-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Propen-1-one, 1-[2-hydroxy-4,6-dimethoxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-methoxy phenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propen-1-one, 1-[2-hydroxy-4,6-dimethoxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-methoxy phenyl)-(70872-24-1)
• EPA Substance Registry System: 2-Propen-1-one, 1-[2-hydroxy-4,6-dimethoxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-methoxy phenyl)-(70872-24-1)

Safety Data

• Hazardous Substances Data: 70872-24-1(Hazardous Substances Data)

Upstream product

• 33523-62-5 1-(2’-hydroxy-4’,6’-dimethoxy-3’-(3’’-methyl-2’’-buten-1’’-yl)phenyl)ethanone 
• 123-11-5 4-methoxy-benzaldehyde 
• 108-73-6 3,5-dihydroxyphenol 
• 480-66-0 2,4,6-trihydroxyacetophenone 
• 74-88-4 methyl iodide 
• 27364-71-2 2',4',6'-trihydroxy-3'-(3-methyl-2-butenyl)acetophenone 
• 870-63-3 prenyl bromide 

Downstream Products

• 791113-03-6 4,2'-dihydroxy-3'-prenyl-4'-ethoxychalcone 

Relevant articles and documents

Design, synthesis and biological evaluation of chalcones as reversers of P-glycoprotein-mediated multidrug resistance

Overexpression of P-glycoprotein (P-gp) is one of the major causes for multidrug resistance (MDR), which has become a major obstacle in cancer therapy. One hopeful approach to reverse the MDR is to develop inhibitors of P-gp in expression and/or function. Here, we designed and synthesized a series of chalcone derivatives as P-gp inhibitors and evaluated their potential reversal activities against MDR. Among them, the most active compound MY3 had little intrinsic cytotoxicity and showed the highest activity (RF = 50.19) in reversing DOX resistance in MCF-7/DOX cells. Further studies demonstrated that MY3 could increase intracellular accumulation of DOX and inhibit expression of P-gp at mRNA and protein levels. More importantly, MY3 significantly enhanced the efficacy of DOX against the tumor xenografts bearing MCF-7/DOX cells with the precondition of unchanged body weight. Therefore, MY3 might represent a promising lead to develop MDR reversal agents for cancer chemotherapy.

Anti-ulcer agent comprising chalcone derivative as effective ingredient and novel chalcone derivative

The present invention relates to an anti-ulcer agent comprising a compound represented by the following general formula I as the effective ingredient, and a novel chalcone derivative included in the compound represented by this general formula I: STR1 wherein X and Y independently stand for a hydrogen atom or together form a single bond, R1 stands for a hydroxyl group, an acetoxy group, a carboxymethoxy group or a methoxycarbonylmethoxy group, R2 stands for a hydrogen atom, an isoprenyl group, isopentyl group or a propyl group, R3 stands for hydroxyl group or a methoxy group, R4 stands for a hydrogen atom, a hydroxyl group or a methoxy group, R5 stands for a hydrogen atom, a hydroxyl group, a methoxy group or an isopentyl group, R6 stands for a hydroxyl group, a methoxy group or a carboxymethoxy group, and R7 stands for a hydrogen atom or a methoxy group.